In in vitro experiments, 111In-DTPA-NLS-trastuzumab radiobioconjugate was six times more cytotoxic than non-labeled trastuzumab towards HER2-overexpressing SK-BR-3 human BC cells. Here, ERBB2 is linked to breast cancer.